title: [Effects of modified inclusion criteria and negative reporting about PSA screening on the number of potentially recruitable patients for the PREFERE study].
abstract: BACKGROUND
  The PREFERE study is currently below expectations. The objective of this study was to investigate the effect of the modification of the inclusion criteria in 2015 on the number of recruitable patients with localized prostate cancer. Furthermore we analyzed whether fewer cases of low-risk prostate cancer were detected in 2014 than in 2010.
  
  
  METHODS
  Prostate biopsies of 2136 patients (9 hospitals) of the years 2010 and 2014 were retrospectively reviewed, regarding the eligibility for participation in the PREFERE study.
  
  
  RESULTS
  According to PREFERE criteria version 3.2, 16.8 % (in 2010) and 16.7 % (in 2014) of the patients fulfilled the inclusion criteria for the study, whereas 41.9 % (in 2010) and 30.1 % (in 2014) of the patients met the criteria in version 5.0.
  
  
  CONCLUSIONS
  Our results indicate that the modified inclusion criteria result in an increase in the number of recruitable patients for the PREFERE study. Furthermore, there were 11.8 % fewer cases of potentially recruitable patients in 2014 than in 2010 by use of version 5.0. This is a possible indication for an altered use of prostate biopsy.
authors.affiliation: Klinik für Urologie und Kinderurologie, Klinikum Fulda, Pacelliallee 4, 36043, Fulda, Deutschland.
authors.forename: J
authors.initials: J
authors.lastname: Mathes
authors.affiliation: Klinik für Urologie, Universitätsklinikum Regensburg, Regensburg, Deutschland.
authors.forename: M
authors.initials: M
authors.lastname: Burger
authors.affiliation: Urologische Klinik und Poliklinik, Technische Universität München, München, Deutschland.
authors.forename: J E
authors.initials: JE
authors.lastname: Gschwend
authors.affiliation: Urologische Klinik und Poliklinik, Universitätsklinikum Rostock, Rostock, Deutschland.
authors.forename: O W
authors.initials: OW
authors.lastname: Hakenberg
authors.affiliation: Klinik für Urologie, Kinderurologie und Urologische Onkologie, Kliniken Essen-Mitte, Essen, Deutschland.
authors.forename: S
authors.initials: S
authors.lastname: Krege
authors.affiliation: Urologische Klinik, Städtisches Krankenhaus Kiel, Kiel, Deutschland.
authors.forename: J
authors.initials: J
authors.lastname: Lehmann
authors.affiliation: Klinik für Urologie, Charité Berlin, Berlin, Deutschland.
authors.forename: K
authors.initials: K
authors.lastname: Miller
authors.affiliation: Klinik für Urologie und Kinderurologie, Vivantes Klinikum Berlin/Friedrichshain, Berlin, Deutschland.
authors.forename: J
authors.initials: J
authors.lastname: Roigas
authors.affiliation: Klinik für Urologie und Kinderurologie, Helios Universitätsklinikum Wuppertal, Wuppertal, Deutschland.
authors.forename: S
authors.initials: S
authors.lastname: Roth
authors.affiliation: Klinik für Urologie und Kinderurologie, Klinikum Fulda, Pacelliallee 4, 36043, Fulda, Deutschland. T.Kaelble.Urologie@klinikum-fulda.de.
authors.forename: T
authors.initials: T
authors.lastname: Kälble
mesh_terms: D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000097:blood*; D004608:Eligibility Determination / Q000379:methods / Q000706:statistics & numerical data*; D005858:Germany / Q000453:epidemiology; D006801:Humans; D008297:Male; D008875:Middle Aged; D018579:Patient Selection; D015995:Prevalence; D017430:Prostate-Specific Antigen / Q000097:blood*; D011471:Prostatic Neoplasms / Q000175:diagnosis* / Q000453:epidemiology / Q000628:therapy*; D015203:Reproducibility of Results; D018570:Risk Assessment / Q000379:methods; D012307:Risk Factors; D012680:Sensitivity and Specificity
chemical_list: D014408:Biomarkers, Tumor; D017430:Prostate-Specific Antigen
keywords: Inclusion criteria; Low-risk prostate cancer; PREFERE study; Prostate biopsy